Skip to main content
Journal cover image

Characterization of the mechanisms of busulfan resistance in a human glioblastoma multiforme xenograft.

Publication ,  Journal Article
Hare, CB; Elion, GB; Colvin, OM; Ali-Osman, F; Griffith, OW; Petros, WP; Keir, S; Marcelli, SL; Bigner, DD; Friedman, HS
Published in: Cancer Chemother Pharmacol
1997

Busulfan is an alkylating agent commonly used in the treatment of chronic myelogenous leukemia and in combination with cyclophosphamide in preparation for allogeneic bone marrow transplantation. Serial treatment of a childhood high-grade glioma xenograft (D-456 MG) with busulfan resulted in a busulfan-resistant xenograft, D-456 MG(BR). Cross-resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea was seen but not resistance to cyclophosphamide or CPT-11. Cytoplasmic levels of glutathione in D-456 MG(BR) were approximately one-half those found in D-456 MG. This depletion could not be explained by levels of glutathione-S-transferase, or by amplification, rearrangement, or increased levels of transcript of gamma-glutamylcysteine synthetase. Furthermore, depletion of glutathione in D-456 MG did not alter busulfan activity. Quantitation of busulfan levels in D-456 MG and D-456 MG(BR) xenografts following treatment of mice at the dose lethal to 10% of the animals demonstrated that significantly lower levels of drug were achieved in D-456 MG(BR). These studies suggest that alterations in drug transport or metabolism of busulfan may play a role in the resistance of D-456 MG(BR) to this alkylator.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Cancer Chemother Pharmacol

DOI

ISSN

0344-5704

Publication Date

1997

Volume

40

Issue

5

Start / End Page

409 / 414

Location

Germany

Related Subject Headings

  • Transplantation, Heterologous
  • Oncology & Carcinogenesis
  • Mice, Nude
  • Mice, Inbred BALB C
  • Mice
  • Male
  • Humans
  • Glutamate-Cysteine Ligase
  • Glioblastoma
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Hare, C. B., Elion, G. B., Colvin, O. M., Ali-Osman, F., Griffith, O. W., Petros, W. P., … Friedman, H. S. (1997). Characterization of the mechanisms of busulfan resistance in a human glioblastoma multiforme xenograft. Cancer Chemother Pharmacol, 40(5), 409–414. https://doi.org/10.1007/s002800050678
Hare, C. B., G. B. Elion, O. M. Colvin, F. Ali-Osman, O. W. Griffith, W. P. Petros, S. Keir, S. L. Marcelli, D. D. Bigner, and H. S. Friedman. “Characterization of the mechanisms of busulfan resistance in a human glioblastoma multiforme xenograft.Cancer Chemother Pharmacol 40, no. 5 (1997): 409–14. https://doi.org/10.1007/s002800050678.
Hare CB, Elion GB, Colvin OM, Ali-Osman F, Griffith OW, Petros WP, et al. Characterization of the mechanisms of busulfan resistance in a human glioblastoma multiforme xenograft. Cancer Chemother Pharmacol. 1997;40(5):409–14.
Hare, C. B., et al. “Characterization of the mechanisms of busulfan resistance in a human glioblastoma multiforme xenograft.Cancer Chemother Pharmacol, vol. 40, no. 5, 1997, pp. 409–14. Pubmed, doi:10.1007/s002800050678.
Hare CB, Elion GB, Colvin OM, Ali-Osman F, Griffith OW, Petros WP, Keir S, Marcelli SL, Bigner DD, Friedman HS. Characterization of the mechanisms of busulfan resistance in a human glioblastoma multiforme xenograft. Cancer Chemother Pharmacol. 1997;40(5):409–414.
Journal cover image

Published In

Cancer Chemother Pharmacol

DOI

ISSN

0344-5704

Publication Date

1997

Volume

40

Issue

5

Start / End Page

409 / 414

Location

Germany

Related Subject Headings

  • Transplantation, Heterologous
  • Oncology & Carcinogenesis
  • Mice, Nude
  • Mice, Inbred BALB C
  • Mice
  • Male
  • Humans
  • Glutamate-Cysteine Ligase
  • Glioblastoma
  • Female